|
The product 'Vita D Injection' won the Formulation Technology Award at the 2019 International Conference of the Korean Pharmaceutical Society
2019.11.27
|
|---|
|
The vitamin D injection product 'Vita D Injection' was recognized for its stability and won the Formulation Technology Award at the 2019 International Conference of the Korean Pharmaceutical Society.
The award-winning technology involves suppressing the formation of soft substances (degradants) in the vitamin D injection, securing its stability, and changing the storage temperature approval from 1–25℃ to 1–30℃. This improvement increases convenience in distribution and storage. Currently, Daehan New Pharm is the only company producing vitamin D injections under the 1–30℃ storage condition.
Vitamin D, specifically calciferol, is classified into D2 (ergocalciferol) and D3 (cholecalciferol). D2 is made from ergosterol, a sterol, while D3 is produced in the skin upon sunlight exposure to 7-dehydrocholesterol. Vitamin D is known for promoting calcium absorption and is part of osteoporosis treatments. Recently, its deficiency has been linked to obesity, diabetes, and heart disease.
Despite the growing importance of vitamin D, modern lifestyles with reduced outdoor activity and frequent use of sunscreen make deficiency common. Since vitamin D3 easily oxidizes to form unstable soft substances, developing vitamin D injections has been challenging.
Daehan New Pharm secured stabilization technology that inhibits the formation of soft substances like trans-cholecalciferol. The company registered two related patents and successfully changed storage conditions to improve convenience. The domestic market for vitamin D injections grew from 12.3 billion won in 2017 to 13.2 billion won in 2018. Daehan New Pharm produces and sells three dosage forms of 'Vita D': 100,000 IU, 200,000 IU, and 300,000 IU. |


Home